Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties. It is a Schedule IV controlled substance.
## Primary Indications
* Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
* Other seizure types may be treated off-label based on expert consensus and clinical judgment.
## Adult Dosing
* **Lennox-Gastaut Syndrome:** Initial dose: 5 mg twice daily. Titrate by 5 mg to 10 mg every week to a target maintenance dose of 10 mg twice daily. Maximum recommended dose: 20 mg twice daily.
* **Other Seizure Types (Off-Label):** Dosing is highly variable and should be individualized. Typical starting doses may range from 5 mg to 10 mg once or twice daily, with gradual titration based on response and tolerability. Maximum doses are not well-established for off-label use and depend on clinical context.
## Pediatric Dosing
* **Lennox-Gastaut Syndrome (2 to <10 years):** Initial dose: 5 mg once daily. Titrate by 2.5 mg to 5 mg every week to a target maintenance dose of 5 mg twice daily. Maximum recommended dose: 10 mg twice daily.
* **Lennox-Gastaut Syndrome (10 years and older):** Same as adult dosing: Initial dose: 5 mg twice daily, titrate to a target of 10 mg twice daily. Maximum recommended dose: 20 mg twice daily.
* **Note:** Pediatric dosing for other seizure types is not established and should be managed by specialists.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. Data is limited, but a lower starting dose and slower titration may be considered.
* **Renal Impairment:** No specific dose adjustment is recommended, but monitor for increased adverse effects.
* **Concomitant Medications:** Consider potential interactions (see Key Drug Interactions).
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
## Adverse Effects
* **Common:** Somnolence, decreased appetite, constipation, irritability, aggression, vomiting, drooling, ataxia, upper respiratory tract infections, pneumonia.
* **Serious:** Severe skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis), suicidal behavior or ideation, withdrawal symptoms (seizures, rebound insomnia, anxiety), respiratory depression (especially when combined with other CNS depressants), paradoxical reactions (agitation, hallucinations).
## Key Drug Interactions
* **CNS Depressants (e.g., opioids, alcohol, other benzodiazepines, sedating antihistamines):** Increased risk of sedation, respiratory depression, and potentially fatal outcomes. Avoid concomitant use or use with extreme caution and the lowest effective doses.
* **CYP1A2 and CYP2C19 Substrates:** Clobazam is a moderate inhibitor of CYP2C19 and a weak inhibitor of CYP1A2. May increase concentrations of drugs metabolized by these enzymes (e.g., certain antidepressants, proton pump inhibitors). Monitor for toxicity of concomitant medications.
* **CYP3A4 Inducers/Inhibitors:** Clobazam is metabolized by CYP3A4. Inducers may decrease clobazam levels, and inhibitors may increase them.
## Monitoring
* Seizure frequency and type.
* Signs of somnolence, sedation, and cognitive impairment.
* Signs of withdrawal upon discontinuation.
* Suicidal ideation or behavior.
* Skin integrity, especially during the initial weeks of treatment or dose changes.
* Concomitant medication levels if clinically indicated.
## Clinical Pearls
* Clobazam is indicated as adjunctive therapy for LGS; it is not typically used as monotherapy for LGS.
* Due to the risk of severe skin reactions, patients should be advised to discontinue clobazam and seek immediate medical attention if a rash develops.
* Withdrawal symptoms can occur upon abrupt discontinuation. Tapering of the dose is recommended.
* The risk of somnolence and cognitive impairment may be dose-related and may increase with concomitant CNS depressants.
* Patients should be monitored for behavioral changes, including aggression and irritability.
***
*This information is intended for clinical use and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant guidelines before making any clinical decisions.*
